AC
FLGT icon

Aperimus Capital’s Fulgent Genetics FLGT Stock Holding History

Aperimus Capital’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$719K Buy
+7,800
New +$623K 1.16% 7

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Aperimus Capital's FLGT Position: Q2 2021 in Review

Aperimus Capital opened a new position in Fulgent Genetics (FLGT) in Q2 2021: 7,800 shares worth $719K. The stake represents 1.16% of the portfolio and ranks #7 among its holdings.

254 funds tracked by Wall St. Rank hold FLGT as of Q2 2021.

  • Aperimus Capital held 7,800 shares of Fulgent Genetics worth $719K as of Q2 2021.
  • Fulgent Genetics was a new Aperimus Capital position in Q2 2021.
  • Fulgent Genetics made up 1.16% of Aperimus Capital's portfolio in Q2 2021, its #7 holding.
  • 254 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2021.

Based on Aperimus Capital's 13F filing for Q2 2021, filed 28 Jul 2021.